{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T03:46:08Z","timestamp":1776138368871,"version":"3.50.1"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T00:00:00Z","timestamp":1602633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.579445","type":"journal-article","created":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T05:27:54Z","timestamp":1602653274000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report"],"prefix":"10.3389","volume":"10","author":[{"given":"Maria Anna","family":"Siciliano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Dastoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"d\u2019Apolito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoletta","family":"Staropoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierfrancesco","family":"Tassone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierosandro","family":"Tagliaferri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vito","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,10,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-year survival outcome for patients with advanced melanoma treated with Pembrolizumab in KEYNOTE-001.","volume":"30","author":"Hamid","year":"2019","journal-title":"Ann Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma.","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade.","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nm.4321","article-title":"Is autoimmunity the Achilles\u2019 heel of cancer immunotherapy?","volume":"23","author":"June","year":"2017","journal-title":"Nat Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.semcancer.2019.08.001","article-title":"Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy.","volume":"59","author":"Queirolo","year":"2019","journal-title":"Semin Cancer Biol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/s41571-020-0352-8","article-title":"Moving towards personalized treatments of immune- related adverse events.","volume":"17","author":"Esfahani","year":"2020","journal-title":"Nat Rev Clin Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer\u2013immune set point.","volume":"541","author":"Chen","year":"2017","journal-title":"Nature."},{"key":"B8","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors.","volume":"19","author":"Sibaud","year":"2017","journal-title":"Am J Clin Dermatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.2174\/1574886313666180730114309","article-title":"Cutaneous adverse events of immune checkpoint inhibitors: a summarized overview.","volume":"14","author":"Plachouri","year":"2019","journal-title":"Curr Drug Saf."},{"key":"B10","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis.","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1016\/j.cellsig.2014.05.014","article-title":"Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.","volume":"26","author":"Schafer","year":"2014","journal-title":"Cell Signal."},{"key":"B12","first-page":"835","article-title":"Mechanism underlying the clinical effects of Apremilast for psoriasis.","volume":"17","author":"Pincelli","year":"2018","journal-title":"J Drugs Dermatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40257-017-0302-0","article-title":"Apremilast: a novel oral treatment for psoriasis and psoriatic arthritis.","volume":"19","author":"Torres","year":"2018","journal-title":"Am J Clin Dermatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s40265-017-0709-1","article-title":"Apremilast: a review in psoriasis and psoriatic arthritis.","volume":"77","author":"Keating","year":"2017","journal-title":"Drugs."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1093\/rheumatology\/key032","article-title":"Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial.","volume":"57","author":"Wells","year":"2018","journal-title":"Rheumatology (Oxford)."},{"key":"B16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jdermsci.2016.12.019","article-title":"Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-a is a biomarker of nivolumab reactivity.","volume":"86","author":"Tanaka","year":"2016","journal-title":"J Dermatol Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1200\/JCO.18.02141","article-title":"Treatment outcomes of immune-related cutaneous adverse events.","volume":"37","author":"Phillips","year":"2019","journal-title":"J Clin Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1159\/000478898","article-title":"Recurrence of Melanoma after starting Apremilast for Psoriasis.","volume":"9","author":"Salopek","year":"2017","journal-title":"Case Rep Dermatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ejca.2019.01.010","article-title":"Successful treatment of psoriasis induced by immune checkpoint inhibitors with apremilast.","volume":"110","author":"Fattore","year":"2019","journal-title":"Eur J Cancer."},{"key":"B20","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.rmcr.2018.03.001","article-title":"Psoriatic arthritis due to nivolumab administration a case report and review of the literature.","volume":"23","author":"Sapalidis","year":"2018","journal-title":"Respir Med Case Rep."},{"key":"B21","doi-asserted-by":"publisher","first-page":"300","DOI":"10.5826\/dpc.0904a11","article-title":"Psoriasis in patients with active lung cancer: is apremilast a safe option?","volume":"9","author":"Apalla","year":"2019","journal-title":"Dermatol Pract Concept."},{"key":"B22","doi-asserted-by":"publisher","first-page":"549","DOI":"10.2217\/imt-2019-0085","article-title":"Psoriatic arthritis induced by anti-PD1 and treated with apremilast: a case report and review of literature.","volume":"12","author":"Nigro","year":"2020","journal-title":"Immunotherapy."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.579445\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T05:27:57Z","timestamp":1602653277000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.579445\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,14]]},"references-count":22,"alternative-id":["10.3389\/fonc.2020.579445"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.579445","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,14]]},"article-number":"579445"}}